Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Point of Care Molecular Diagnostics Market revenue to cross USD 2.8 Bn by 2026: Global Market Insights, Inc.

Major point of care (PoC) molecular diagnostics market players include Bio-Rad Laboratories, Abbott Laboratories, Sysmex, Danaher, Vircell.

Selbyville, Delaware, Sept. 21, 2020 (GLOBE NEWSWIRE) --

According to latest report “PoC Molecular Diagnostics Market by Technology (PCR, In Situ Hybridization, Sequencing, Isothermal Amplification), Application (Infectious Disease, {Flu, Respiratory Syncytial Virus (RSV), Tuberculosis (TB), HIV, Gonorrhea, Chlamydia, Hepatitis C, Hepatitis B}, Oncology, Hematology), End-use (Hospitals, Clinics), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026”, by Global Market Insights, Inc., the market valuation of point of care (PoC) molecular diagnostics will cross $2.8 billion by 2026. Strategic initiatives for developing innovative PoC molecular diagnostics assays and instruments will accelerate the market growth.

Point of care molecular diagnostics tests deliver several benefits from enhancing patient care to limiting healthcare expenditure. High-quality diagnostic tests are widely available in developed countries, while developing economies face a shortage of high-quality diagnostic tools. Therefore, there is a rise in R&D investment by public and private organizations for delivering cost-effective and high-quality diagnostic tools to satisfy the growing consumer demand in developing countries of the Asia Pacific and Latin America.

Request for a sample of this research report @

https://www.gminsights.com/request-sample/detail/2210

The situ hybridization segment held over 20% of point of care molecular diagnostics market share in 2019. Rising utilization of in-situ hybridization in laboratories as well as research activities to diagnose infectious diseases, chromosomal abnormalities and cancer will contribute towards segment progression. Comparative genomic hybridization (CGH) and fluorescence in-situ hybridization (FISH) are effective techniques in detecting numerous genetic variations including aneuploidy, congenital abnormalities, and deletions.

The infectious disease application segment valuation was more than USD 780 million in 2019 due to increasing incidence of flu across the globe. For instance, according to CDC estimates, in the U.S. around 490,561 individuals were hospitalized and over 16 million people suffering from flu visited hospitals in the year 2018-2019. Moreover, rising laboratory capacity for the diagnosis of influenza among elderly population base, newborn babies and individual with certain chronic illnesses will further fuel the industry growth.